More on CLNN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.34 |
|
|||
| Open | $0.34 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.36 | ||||
| Day Low | $0.33 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 382,088 | ||||
- Form ARS Clene Inc. For: Dec 31
- Form DEFA14A Clene Inc.
- Form DEF 14A Clene Inc. For: Dec 31
- Form 8-K Clene Inc. For: Apr 16
- Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
- Form 4 Clene Inc. For: Apr 09 Filed by: General Resonance LLC
- Form 8-K Clene Inc. For: Apr 03
- Form PRE 14A Clene Inc. For: Dec 31
- IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Entities mentioned with CLNN
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Maxim Group | View Related Stories »
- Canaccord Genuity | View Related Stories »
- S1 | View Related Stories »
- Show More...
